GB Innomech Group expands its commercial team to better serve high-tech companies in Cambridgeshire

Ely- based GB Innomech Group, specialists in process automation and low to medium volume product manufacture, have appointed Adrian SC Brown as Business Development Manager to accelerate growth by securing new commercial opportunities for the Nexus IE and Innomech brands. The new senior position follows the recent appointment of Sue Bell as Group Projects Administrator and reinforces GB Innomech’s desire to expand its market footprint to SMEs in the local area.

Innomech designs and develops industrial process automation technology while its sister company, Nexus IE, specialises in providing customers with an end-to-end manufacturing service, from procurement and build through to testing, maintenance and ongoing product servicing, supporting start-ups and SME’s in the commercialisation of their products.

Adrian Brown has extensive experience of the technology and pharmaceutical industries and has held senior positions at a number of well-known Cambridge companies, including Sigma Aldrich, Cambridge Reactor Design Ltd and GlaxoSmithKline. Sue Bell is an experienced Project Manager, with excellent planning, administration and procurement skills, as well as extensive knowledge of OHSAS 18001, SO 14001, BS EN ISO 9001 certification processes. She is also NEBOSH (General Certificate in Health & Safety at Work) qualified.

Operating from a purpose-built eco-sustainable innovation centre, Nexus IE and Innomech have the means to support manufacturing businesses with a desire to run more efficiently or productively, or convert technical innovations into real-world products. Both businesses are ISO 9001 certified, and possess the skillset needed to satisfy the strictly regulated pharmaceutical and med tech markets.

“I’m looking forward to this new opportunity,” comments Adrian SC Brown, Business Development Manager of GB Innomech Group.” Collectively, both brands have over 35 years’ experience of working with med tech and pharmaceutical companies and I hope to generate exciting new opportunities in the high-tech space”

Ends